Last update 01 Nov 2024

Pellucid Lifesciences Pvt Ltd.

Private Company|

India

Private Company|

India

Last update 01 Nov 2024

Overview

Pipeline

Deal

Translational Medicine

Overview

Clinical Trials associated with Pellucid Lifesciences Pvt Ltd.

CTRI/2024/04/066125 / Not yet recruitingNot Applicable

A Double-Blind, Randomized, Two-Arm, Placebo-Controlled, Comparative Clinical Study to Evaluate the Safety and Efficacy of Bacillus coagulans BCP92 in Healthy Adult Subjects. - NIL

Start Date10 May 2024

Sponsor / Collaborator

Pellucid Lifesciences Pvt Ltd.

CTRI/2023/03/051167 / CompletedPhase 2

A Prospective, Interventional, Randomized, Parallel, Double blind, Multicenter, Placebo controlled, Clinical Study to evaluate the efficacy and safety of Bacillus Coagulans BCP92 (MTCC 25460) in adults with irritable bowel syndrome.

Start Date10 Apr 2023

Sponsor / Collaborator

Pellucid Lifesciences Pvt Ltd.

100 Clinical Results associated with Pellucid Lifesciences Pvt Ltd.

0 Patents (Medical) associated with Pellucid Lifesciences Pvt Ltd.

Literatures (Medical) associated with Pellucid Lifesciences Pvt Ltd.

02 Aug 2024·Medicine

Role of Bacillus coagulans (Heyndrickxia coagulans)BCP92 in managing irritable bowel syndrome: A randomized, double-blind, multicenter, placebo-controlled clinical trial

Article

Author: Shaikh, Sohel S. ; Kumar, Sanjay

Background:Irritable bowel syndrome (IBS) is a major global healthcare burden that requires effective and well-tolerated intervention. This study aimed to investigate the effectiveness and safety of Bacillus coagulans BCP92, a probiotic, in managing IBS symptoms.Methods:This randomized controlled trial included 100 participants who strictly adhered to the protocol. Various parameters such as IBS severity, digestive symptom frequency, gastrointestinal symptom frequency, stool consistency, interleukin-6 levels, stress relief, and anxiety levels were evaluated over 12 weeks.Results:B. coagulans BCP92 significantly improved IBS severity (P < .001), and gastrointestinal symptom frequency (P < .001) compared with that in the control group. The stool consistency significantly improved (P < .001). Mental stress relief was remarkable (P = .001), differentiating the test and control groups. No significant change in interleukin-6 levels was observed; however, the safety assessment revealed an excellent profile with no reported severe adverse events.Conclusion:B. coagulans BCP92 is one of the most promising therapeutic options for the management of IBS because it has shown significant efficacy in alleviating symptoms among patients suffering from this condition, resulting in improved stool consistency changes in addition to improving overall mental well-being for its users, thereby foreseeing the elimination of any potential side effects experienced during the implementation of this approach strategy within our health care system, thereby improving patient outcomes and leading to individualization of treatment plans among all individuals diagnosed with this disease entity who may have symptoms, including abdominal pain or discomfort associated with changes in bowel habits.

02 Jan 2024·Letters in Applied Microbiology

In-silico analysis of probiotic attributes and safety assessment of probiotic strain Bacillus coagulans BCP92 for human application

Article

Author: Sengupta, Priyajit ; Ghelani, Anjana ; Chettiar, Shiva Shankaran ; Patel, Alpesh ; Jhala, Devendrasinh ; Malik, Anis ; Shaikh, Sohel S

AbstractThe whole genome sequence (WGS) of Bacillus coagulans BCP92 is reported along with its genomic analysis of probiotics and safety features. The identification of bacterial strain was carried out using the 16S rDNA sequencing method. Furthermore, gene-related probiotic features, safety assessment (by in vitro and in silico), and genome stability were also studied using the WGS analysis for the possible use of the bacterial strain as a probiotic. From the BLAST analysis, bacterial strain was identified as Bacillus (Heyndrickxia) coagulans. WGS analysis indicated that the genome consists of a 3 475 658 bp and a GC-content of 46.35%. Genome mining of BCP92 revealed that the strain is consist of coding sequences for d-lactate dehydrogenase and l-lactate dehydrogenases, 36 genes involved in fermentation activities, 29 stress-responsive as well as many adhesions related genes. The genome, also possessing genes, is encoded for the synthesis of novel circular bacteriocin. Using an in-silico approach for the bacterial genome study, it was possible to determine that the Bacillus (Heyndrickxia) coagulans strain BCP92 contains genes that are encoded for the probiotic abilities and did not harbour genes that are risk associated, thus confirming the strain’s safety and suitability as a probiotic to be used for human application.

100 Deals associated with Pellucid Lifesciences Pvt Ltd.

100 Translational Medicine associated with Pellucid Lifesciences Pvt Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Dec 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Pellucid Lifesciences Pvt Ltd.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 23 Dec 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing